The launch of the NIHR Industry hub last week, the launch of UKRI/Innovate strategy this Thursday and a landmark Mansion House event tomorrow all signal forward momentum on Industrial Strategy.
In this guest blog, Valerie Pinkerton, UK TNFD & Transition Plans Lead at the Green Finance Institute, explores why nature-related risks are becoming increasingly important for the pharmaceutical and biotechnology sector.
BIA member Asma Aslam, Senior Corporate Tax Manager at Frazier & Deeter, explores how a period of tighter capital and greater scrutiny has reshaped expectations around execution, value creation and operational discipline.
In this guest blog, Dr David Montgomery, co-founder of PM Life Sciences, discusses the reality of UK-originated assets, companies and long-term economic returns ending up overseas despite record public investment and a world-class discovery base.
In this blog, Jane Wall, Managing Director at BIA, reflects on the insights from our sell-out Women in Biotech 'Big WiB' event held at Hinxton Hall, Cambridge, in the lead-up to International Women’s Day.
In this blog, Emily Klein reflects on the importance of Rare Disease Day in bringing visibility to those affected by a rare condition and serving as a focal point for advocacy in this space.
With Rare Disease Day coming up next weekend, we at BIA are taking time to reflect on our important advocacy and thought leadership in this space, but also on what we hope to achieve in terms of boosting our influence collectively alongside our Charity Partner of the Year.
In this guest blog, Katherine Powers, Life Sciences Senior Analyst at RSM US, and Max Stanyard, Life Sciences Senior Analyst at RSM UK, highlight the investment uncertainty in the UK-US life sciences ecosystem.
The UK’s life sciences and biotech sector has long been recognised for its scientific excellence, vibrant innovation and dynamic startup culture around the globe. In the past year, interest in our business ecosystem from international partners has markedly accelerated.
In this guest blog, Richard Turner, Senior Managing Director at FTI Consulting, discusses how licence and collaboration agreements in life sciences can create significant tax consequences.
It’s been an energising week across the UK life sciences landscape, marked by major investment, important conversations and new opportunities for our community.
In this guest blog, Hareklea Markides, Innovation Lead - Medicines Manufacturing at Innovate UK, reflects on the UK BioIndustry Association's (BIA) annual #bioProcessUK conference.
TechBio’s potential to both transform our sector and provide precision diagnosis and care to patients is well recognised, and TechBio Boost is playing a vital role in scaling companies in this space.
In this blog, Abby Clark, Manufacturing Programme Manager at BIA, highlights some of the key achievements of BIA and ABPI’s Medicines Manufacturing Industry Partnership (MMIP).
In this guest blog, BIA member Asma Aslam, Senior Corporate Tax Manager at Frazier & Deeter, shares expert insight into the UK’s evolving R&D tax relief landscape for life sciences companies.
A bumper update today as we highlight the critical importance of building UK capability and innovation leadership as geopolitics continues to provide uncertainty.
